Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Hematopoiesis in Monoclonal B Cell Lymphocytosis (MBL) and B-Chronic Lymphocytic Leukemia (CLL) Versus Healthy Age-Matched Control Subjects

NCT ID: NCT06536452Sponsor: Mayo ClinicLast updated: 2026-03-31

Summary

This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.

Detailed description

PRIMARY OBJECTIVES: I. Determine the cellular and mechanistic basis of bone marrow (BM) hematopoietic dysfunction in untreated MBL and CLL patients. II. Determine if MBL and CLL B cell derived cellular products directly alter the differentiation and functional capacities of Hematopoietic Stem and Progenitor Cells (HSPCs). III. Utilize the Emu-Tcl1 transgenic mouse model to determine how MBL and CLL patient-derived cellular products alter BM hematopoiesis. OUTLINE: This is an observational study. Patients undergo blood sample collection and bone marrow aspiration and biopsy and have their medical records reviewed on study.

Arms & interventions

  • OtherNon-Interventional Study

    Non-interventional study

Outcome measures

Primary

  • Effects of MBL on bone marrow function

    Samples collected from healthy participants and participants with MBL will be compared for differences in bone marrow function (i.e., ability to fight off infection). Results will be descriptive. With participant permission, samples will be stored for future research use.

    Time frame: Baseline

  • Effects of CLL on bone marrow function

    Samples collected from healthy participants and participants with CLL will be compared for differences in bone marrow function (i.e., ability to fight off infection). Results will be descriptive. With participant permission, samples will be stored for future research use.

    Time frame: Baseline

Eligibility criteria

Sex: AllAge: 40 Years and olderHealthy volunteers: Yes
Inclusion Criteria: * Subjects in the CLL cohort who are eligible for these studies will have a clinically established diagnosis of CLL as assessed by flow cytometry and will include subjects who * Remain untreated * Are currently being treated * Who have already been treated * Subjects in the MBL cohort will have a clinically established diagnosis of MBL * Healthy age-matched control subjects * Healthy younger control subjects aged \> 40 years Exclusion Criteria: * Anyone under 40 * Healthy control subjects must not have a diagnosis of CLL or MBL

Study locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting
Clinical Trials Referral Office · Contact
855-776-0015mayocliniccancerstudies@mayo.edu
Neil E. Kay, M.D. · Principal Investigator
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects | Cancerify